Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

July 27th 2021

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Genomic Prostate Score Could Impact Treatment Decisions in Diverse Prostate Cancer Populations

July 27th 2021

The net effect of the Oncotype DX Genomic Prostate Score in patients with favorable-risk prostate cancer was to move away from active surveillance, altering the understanding of how prognostic molecular assays that generate probabilities of poor outcome can impact treatment decisions in diverse populations.

Dr. Pieczonka on the Rationale to Evaluate VERU-111 in mCRPC

July 26th 2021

Christopher Pieczonka, MD, discusses the rationale to evaluate sabizabulin in men with metastatic castration-resistant prostate cancer in the phase 3 VERACITY trial.

Genotypic and Phenotypic Biomarkers in Prostate Cancer

July 23rd 2021

A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.

Prostate Cancer Disease Complexity and Testing

July 23rd 2021

Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.

The VISION Study in Metastatic CRPC

July 23rd 2021

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

PSMA PET Imaging in Advanced Prostate Cancer

July 23rd 2021

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.

PSMA as a Biomarker in Advanced Prostate Cancer

July 23rd 2021

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.

Dr. Burnham on Closing the Gap in Health Disparities in Prostate Cancer

July 22nd 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

New Tool Could Help Predict Outcomes with 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer

July 22nd 2021

A new prognostic tool, the nomogram, has demonstrated the ability to predict outcomes following treatment with lutetium-177 prostate-specific membrane antigen in patients with metastatic castration-resistant prostate cancer, and could potentially be used to inform future trial designs and clinical decisions.

Dr. Lyou on Emerging Biomarkers in Prostate Cancer

July 19th 2021

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Ipatasertib/Abiraterone Data Published in Lancet Underscore the Combo’s Frontline Potential in PTEN-Loss mCRPC

July 19th 2021

Ipatasertib plus abiraterone acetate and prednisone demonstrated a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer with PTEN loss, according to findings from the ongoing phase 3 IPATential150 trial now published in The Lancet.

Dr. Lyou on Sequencing Apalutamide in Prostate Cancer

July 16th 2021

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Darolutamide/ADT Significantly Improves OS in Nonmetastatic CRPC, Irrespective of Crossover

July 15th 2021

Neal Shore, MD, FACS, discusses the impact of crossover from placebo to darolutamide on OS benefit in patients with nmCRPC enrolled to the ARAMIS trial, and next steps for the androgen receptor inhibitor.

Dr. Burnham on Health Disparities in Prostate Cancer

July 14th 2021

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

Addition of Focal Boost to Intraprostatic Lesions in EBRT Improves Biochemical DFS in Localized Prostate Cancer

July 14th 2021

The addition of a focal boost to the intraprostatic lesion was found to improve biochemical disease-free survival in patients undergoing treatment with external beam radiotherapy for localized intermediate- and high-risk prostate cancer.

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

July 14th 2021

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Dr. Tagawa on the Utility of Radium-223 in Prostate Cancer

July 14th 2021

Scott Tagawa, MD, MS, FACP, discuses the benefits of radium-223 dichloride in prostate cancer.

Dr. Dreicer on the Initial Findings With Sabizabulin in mCRPC

July 13th 2021

Robert Dreicer, MD, discusses the initial findings with sabizabulin in metastatic castration-resistant prostate cancer.

Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate Cancer

July 12th 2021

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.